Acute Myeloid Leukemia Clinical Trial
Amifostine and Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. Chemoprotective drugs, such as amifostine, may protect normal cells from the side effects of chemotherapy.
PURPOSE: Phase I trial to study the effectiveness of amifostine in treating patients with newly diagnosed acute myeloid leukemia who are receiving idarubicin plus cytarabine.
Full Description
OBJECTIVES:
Determine whether amifostine provides systemic protection against the nonhematologic side effects of idarubicin (IDR) during induction therapy of acute myeloid leukemia (AML), allowing the dose of idarubicin to be escalated.
Determine the maximum tolerated dose of idarubicin when amifostine is used as a chemotherapy protectant.
Determine the incidence and severity of dose limiting hypotension in patients receiving amifostine and the ability to offset this side effect with vasoconstrictive agents.
Determine whether any additional side effects of amifostine are dose limiting in patients with AML treated with IDR and cytarabine (ARA-C).
Monitor the frequency of alopecia, mucositis, diarrhea, and septicemia involving enteric pathogens in these patients.
Determine the requirement for intravenous hyperalimentation in patients receiving amifostine, IDR, and ARA-C.
OUTLINE: This is a dose escalation study of idarubicin (IDR).
Patients receive amifostine IV over 15 minutes, followed 15-30 minutes later by chemotherapy. Idarubicin IV is administered over 15 minutes on days 1-3. Cytarabine is administered by continuous infusion on days 1-7. Patients may receive 1 additional course of treatment, if necessary.
Cohorts of 3-6 patients each are treated at each dose level of idarubicin. Dose escalation is discontinued when 2 or more patients experience dose limiting toxicity.
Patients are followed at 3 months.
PROJECTED ACCRUAL: A maximum of 36 patients will be accrued for this study.
Eligibility Criteria
DISEASE CHARACTERISTICS:
Newly diagnosed acute myeloid leukemia (AML)
M0-M2, M4-M7
Histologically proven by bone marrow aspirate and biopsy (requirement may be waived for patients with overt leukemia in the peripheral blood)
M3 (acute promyelocytic leukemia) patients excluded unless already treated with trans retinoic acid
Evaluable disease
PATIENT CHARACTERISTICS:
Age:
18 and over
Performance status:
Karnofsky 60-100%
ECOG 0-2
Life expectancy:
At least 3 months
Hematopoietic:
Not specified
Hepatic:
SGOT/SGPT no greater than 2.5 times upper limit of normal
Renal:
Creatinine no greater than 2.0 mg/dL
Cardiovascular:
Ejection fraction at least 50%
Must be able to stop taking antihypertensive medication 24 hours prior to cytarabine administration
Other:
No preexisting severe organ dysfunction
No history of underlying medical or psychiatric illness that may impair the patient's ability to participate in the study
Not pregnant or nursing
Effective contraception required of fertile patients
PRIOR CONCURRENT THERAPY:
Biologic therapy:
Not specified
Chemotherapy:
See Disease Characteristics
No prior cytotoxic therapy for AML
No prior amifostine
At least 1 month since chemotherapy
Endocrine therapy:
Not specified
Radiotherapy:
At least 1 month since radiotherapy
Surgery:
Not specified
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
Philadelphia Pennsylvania, 19107, United States
How clear is this clinincal trial information?
Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.